Barclays
SPRY icon

Barclays’s ARS Pharmaceuticals SPRY Stock Holding History

Barclays’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
126,261
+42,092
+50% +$362K ﹤0.01% 2784
2026
Q1 		$676K Sell
84,169
-112,218
-57% -$1.08M ﹤0.01% 2997
2025
Q4 		$2.29M Sell
196,387
-32,182
-14% -$313K ﹤0.01% 2846
2025
Q3 		$2.3M Sell
228,569
-393,666
-63% -$5.65M ﹤0.01% 2789
2025
Q2 		$10.9M Buy
622,235
+490,200
+371% +$7.07M ﹤0.01% 1523
2025
Q1 		$1.66M Sell
132,035
-26,145
-17% -$315K ﹤0.01% 2771
2024
Q4 		$1.67M Buy
158,180
+46,514
+42% +$651K ﹤0.01% 3039
2024
Q3 		$1.62M Buy
111,666
+73,127
+190% +$870K ﹤0.01% 3025
2024
Q2 		$328K Buy
38,539
+8,666
+29% +$76.9K ﹤0.01% 3295
2024
Q1 		$305K Sell
29,873
-10,501
-26% -$78.3K ﹤0.01% 3890
2023
Q4 		$221K Buy
40,374
+22,597
+127% +$99K ﹤0.01% 4372
2023
Q3 		$67.2K Sell
17,777
-2,683
-13% -$17.6K ﹤0.01% 3737
2023
Q2 		$137K Sell
20,460
-15,322
-43% -$102K ﹤0.01% 3423
2023
Q1 		$233K Buy
35,782
+14,972
+72% +$115K ﹤0.01% 3701
2022
Q4 		$178K Buy
20,810
+825
+4% +$5.35K ﹤0.01% 3902
2022
Q3 		$106K Sell
19,985
-912
-4% -$4.49K ﹤0.01% 3524
2022
Q2 		$89K Buy
20,897
+3,792
+22% +$13.2K ﹤0.01% 3820
2022
Q1 		$60K Buy
+17,105
New +$74.5K ﹤0.01% 4041

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Barclays's SPRY Position: Q2 2026 in Review

Barclays increased its ARS Pharmaceuticals (SPRY) stake by 50% in Q2 2026, buying an estimated $362K and bringing the position to 126,261 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2784.

Barclays first reported a position in SPRY in Q1 2022 and has held it in 18 quarters since. The position peaked at $10.9M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Barclays held 126,261 shares of ARS Pharmaceuticals worth $1.01M as of Q2 2026.
  • Barclays bought 42,092 ARS Pharmaceuticals shares in Q2 2026, an estimated $362K.
  • ARS Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2784 holding.
  • Barclays first reported a position in ARS Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Barclays's ARS Pharmaceuticals position peaked at $10.9M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.